TaiMed Biologics

Company Overview

Company Headquarters

3F., NO. 607, Ruiguang Rd.
Neihu Dist.
Taipei City, 11492
Taiwan

View Phone No.

Company Description

TaiMed Biologics Inc. (4147.TWO) is a prominent Taiwanese biopharmaceutical company, established in 2007. With a wealth of experience in developing and manufacturing monoclonal antibodies (mAb), we have achieved a major milestone by introducing Trogarzo® (TMB-355), the first and only mAb for HIV treatment in the US and Europe, to the market.

Expedite advancement of your antibody molecules
from early stage to commercialization

About Us

TaiMed Biologics Inc. (4147.TWO), founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®, TMB-355).

Our Advantages

• Competitive costs
High-quality labor at a competitive local cost
• Flexible batch sizes
Pilot to full commercial scales
(50L, 200L, 500L, 2000L single-use bioreactors)
• Single-use technology
Use of single-use technology
that prevents cross-contamination
• cGMP ready

Expedite your product launch from Experienced Team

We strive to propel your important antibody molecules from development to market launch with the highest level of scrutiny to Quality, Cost, and Logistical needs. With TaiMed’s successful regulatory filing experiences with FDA and EMA, our regulatory affairs team can provide the necessary support to prepare regulatory dossiers for IND, BLA, and MAA submissions.

Contract Development & Manufacturing Organization Service

Our State-of-the-art cGMP Facility can produce preclinical, clinical, and eventual commercial batches using single-use technology and a broad spectrum of analytical testing instruments.

Our CDMO Service covers GMP manufacturing, upstream/downstream process development, analytical method development and validation, formulation development, and stability testing of monoclonal antibody drug substances.

Our team has built vast development and manufacturing experiences. We also have successfully developed and commercialized our own monoclonal antibody.

We offer flexible solutions based on your needs and are committed to supporting the advancement of your project.

TaiMed Biologics Pipeline

We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. We look forward to working with you. To get more information, please CONTACT US NOW.

Your success is our priority!

We are excited to share that TaiMed Biologics will be attending BioJapan 2023 in Yokohama. Our aim is to connect with innovators who are interested in licensing opportunities for our HIV therapies. Specifically, we are seeking a global marketing partner for our commercialized product, Trogarzo, which is currently the only approved mAb for HIV therapy in the US. Additionally, we are looking for a co-development and licensing partner for our clinical stage mAb combination. This product has the potential to become the world's first complete regimen for HIV therapy based on mAb. We look forward to exploring the possibilities that await us at this event!